Park Medi World Limited has released the transcript of its earnings conference call held on May 13, 2026, discussing the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript is available on the company's investor relations website.

Financial Performance FY26

The company reported its highest-ever annual revenue of INR1,679 crores for the financial year ended March 31, 2026, representing a year-on-year growth of 21%. Profit after tax (PAT) for the year stood at INR274 crores, a 27% increase compared to the previous year. The EBITDA for the year was INR444 crores, up 20% year-on-year, with an EBITDA margin of 26% and a net profit margin of 16%.

Operational Highlights

During FY26, the company added 610 beds, increasing its capacity from 3,000 beds to 3,610 beds as of March 31, 2026. This included a new 250-bed facility in Bathinda and a 360-bed unit in Agra. Network occupancy for Q4 FY26 stood at 62.5%, while full-year occupancy improved by 244 basis points to 64.1%. The company served approximately 8.7 lakh patients during the financial year, the highest in its history.

Q4 FY26 Results

For the fourth quarter, total revenue stood at INR460 crores, a growth of 30% year-on-year. Operating EBITDA for the quarter was INR127 crores, up 44% year-on-year with a margin of 28%. Profit after tax for Q4 was INR77 crores, registering a growth of 47% year-on-year with a PAT margin of 17%.

Balance Sheet and Future Outlook

As of March 31, 2026, the gross term debt was INR28 crores, significantly reduced from INR450 crores in the previous year. The bank balance increased to INR352 crores, including fixed deposits of INR314 crores. The company has 1,500 beds under execution, expected to be operational by March 2028, which will take the total bed capacity to 5,460.

Park Medi World Limited convened its Board of Directors meeting on May 12, 2026, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board considered and approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Statutory auditors Agiwal & Associates, Chartered Accountants, issued an unmodified opinion on both the standalone and consolidated financial results. The meeting commenced at 08:00 A.M. (IST) and concluded at 10:36 A.M. (IST), with the disclosure signed by Abhishek Kapoor, Company Secretary and Compliance Officer. Subsequently, pursuant to Regulation 47 of the SEBI Listing Regulations, the company published newspaper advertisements on May 13, 2026 in 'The Economic Times' (English) and 'Navbharat Times' (Hindi), disclosing extracts of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

FY26 and Q4 Performance Highlights

FY26 marked the strongest year in the company's history, delivering record performance across every key metric while simultaneously executing the largest annual capacity expansion in its two-decade journey. For the full year, the company recorded its highest-ever revenue of INR 16,794 mn, representing 21% growth year-on-year. EBITDA reached INR 4,443 mn, up 20% YoY, with an EBITDA margin of 26.5%. Net profit for FY26 stood at INR 2,736 mn, up 27% YoY, with a net profit margin of 16.3%, reflecting an expansion of 83 bps YoY. Cash from operations for the year was INR 3,291 mn. The company reported negligible term bank debt of INR 282 mn as of March 31, 2026, and strong liquidity with INR 3,141 mn in fixed deposits and total cash and cash equivalents (including other balances) of INR 5,509 mn. Debtor days improved significantly from 161 days as of March 31, 2025 to 129 days as of March 31, 2026.

For Q4, the company delivered its highest-ever quarterly revenue of INR 4,604 mn, up 30% YoY. Q4 EBITDA came in at INR 1,274 mn, up 44% YoY, with an EBITDA margin of 27.7%, expanding 268 bps YoY. Q4 net profit was INR 768 mn, up 47% YoY, with a net profit margin of 16.7%, expanding 188 bps YoY. The key consolidated financial metrics are summarised below:

Consolidated Financial Performance

Park Medi World delivered robust consolidated financial results for FY26, with revenue from operations rising significantly year-on-year. The group's total income for the full year reached ₹17,109.65 million, compared to ₹14,259.81 million in the previous year, while profit after tax for the full year stood at ₹2,735.57 million, up from ₹2,154.41 million. The following table summarises the detailed consolidated financial performance:

Profit attributable to owners of the company for FY26 stood at ₹2,581.20 million, while non-controlling interests accounted for ₹154.37 million. The consolidated balance sheet as at March 31, 2026 reflected total assets of ₹28,131.46 million, up from ₹21,392.16 million in the prior year, with total equity rising to ₹21,042.96 million from ₹11,188.62 million. Consolidated cash and cash equivalents at the end of the year stood at ₹2,368.50 million, compared to ₹1,030.04 million in the prior year, with net cash generated from operating activities at ₹3,290.94 million.

Standalone Financial Performance

On a standalone basis, Park Medi World also reported strong growth. Revenue from operations for FY26 was ₹1,289.65 million compared to ₹915.82 million in FY25. The standalone results are summarised below:

The standalone balance sheet as at March 31, 2026 showed total assets of ₹9,167.56 million, up from ₹3,196.25 million, with total equity growing to ₹8,600.24 million from ₹1,141.86 million. Cash and cash equivalents at the end of the year stood at ₹854.83 million, compared to ₹19.83 million in the prior year. Net cash generated from operating activities on a standalone basis was ₹174.18 million, while net cash used in investing activities was ₹4,809.17 million, primarily reflecting investments in subsidiaries of ₹2,375.60 million and capital expenditure of ₹665.15 million.

IPO, Acquisitions, and Corporate Developments

During FY26, Park Medi World completed an initial public offering (IPO) of 56,790,123 equity shares with a face value of INR 2 each at an issue price of INR 162 per share, comprising a fresh issue of 47,530,864 shares and an offer for sale of 9,259,259 shares. The company's equity shares were listed on NSE and BSE on December 17, 2025. Total IPO proceeds of ₹7,700.00 million were raised, of which ₹7,023.02 million had been utilised as at March 31, 2026, with ₹676.98 million pending utilisation. The utilisation of IPO proceeds is detailed below:

The company undertook several inorganic growth initiatives during the year. It acquired 100% shareholding in K P S Wellness Private Limited (360-bed capacity) on January 30, 2026 for INR 1,500 million — with a resulting goodwill of INR 1,188.74 million — and SVPD Healthcare Private Limited on March 20, 2026 for INR 950 million, with goodwill of INR 745.63 million. Additionally, the acquisition of Krishna Super-Speciality Hospital (operating through Mahip Hospital Private Limited, a 250-bed facility with 70 ICU beds) was approved for INR 400 million, with goodwill of INR 538.22 million recognised. Blue Heavens Health Care Private Limited, a wholly owned subsidiary, acquired Durha Vitrak Private Limited (operating Febris Multispeciality Hospital) for INR 506.80 million, with goodwill of INR 246.06 million. All acquisitions have been accounted for as business combinations using the acquisition method under Ind AS 103, with purchase price allocations on a provisional basis. Entities acquired during FY26 contributed INR 252.46 million in revenue and INR (55.99) million in profit before tax. FY26 saw a 20% capacity addition with 610 beds added through acquisitions in Bhatinda (250 beds) and Agra (360 beds), taking bed capacity to 3,610 beds as of March 31, 2026. On April 10, 2026, the company commenced operations at an advanced multi-super specialty hospital in Panchkula, a 350-bed facility with modular operation theatres and automated laboratories, taking bed capacity to 3,960 beds. The completion of the acquisition of Febris Multi-Superspeciality Hospital (200 beds) in Narela, Delhi was also noted, with the facility expected to be commissioned in Q2 FY27. The company has also secured requisite approvals for a 150-bed expansion at its Mohali facility, taking its total capacity to 500 beds, expected to be operational within 12–15 months.

Management Commentary

Commenting on the overall performance, Dr. Ajit Gupta, Chairman, and Dr. Ankit Gupta, Managing Director, Park Medi World, said: "FY'26 was the finest year in Park Medi World's history — a year in which we delivered record financial and operating performance, executed our largest-ever capacity addition, and strengthened our balance sheet, all simultaneously. That combination — growth, profitability, and financial discipline moving in the same direction at the same time — is the clearest possible validation of the model we have built over two decades. Post our IPO, we remain firmly focused on disciplined capital allocation, balance sheet strength, and measured expansion. Our immediate priorities are the seamless integration of acquired assets, improving utilisation across newer facilities, and sustaining the profitability that we have delivered. Over the medium term, we will continue to selectively pursue growth opportunities while maintaining our unwavering commitment to delivering affordable, high-quality healthcare and creating long-term value for all our stakeholders."

Management Change and Trading Window

The board noted that Mr. Manoj Khanna, Chief Human Resource Officer and Senior Management Personnel, will be transitioning to a different role within the Park Group of Hospitals as Regional Head (GTR Circle - 4 units). Consequently, he ceased to be a Senior Management Personnel of the company with immediate effect from May 12, 2026. In continuation of its earlier communication dated March 27, 2026, Park Medi World informed that the trading window for trading in the company's securities shall continue to remain closed until the end of business hours on Thursday, May 14, 2026. This restriction applies to all designated persons, including their immediate relatives, in accordance with the company's Code of Conduct. The financial results are available on the company's website at https://www.parkhospital.in/ and on the websites of BSE Limited and National Stock Exchange of India Limited.

About Park Medi World Limited

Park Group of Hospitals is North India's 2nd largest hospital chain, currently operating 16 hospitals with a combined capacity of 3,960 beds. The company is in the process of executing 1,500 beds of additional capacity across 5 hospitals slated for commissioning by FY28. The group has established a strong presence across 14 cities in 5 states — Agra, Ambala, Behror, Bhatinda, Delhi, Faridabad, Gurugram, Jaipur, Karnal, Mohali, Panchkula, Panipat, Patiala, and Sonipat — serving millions of patients across metropolitan and regional communities. The group offers a comprehensive range of clinical services spanning super-specialities including cardiology, neurology, oncology, orthopaedics, gastroenterology, critical care, nephrology, organ transplants, gene therapy, stem-cell therapy, and women and child health.